DOCSLIB.ORG

Innovative Research of America(IRA)公司专业动物皮

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Innovative Research of America(IRA)公司专业动物皮 中国总代：上海起福生物科技有限公司 Innovative Research of America(IRA)公司专业动物皮 下嵌入式给药专业供应商，公司专利的 Matrix-Driven Delivery 系统使药物的长期等量的释放得到了保证，释放时间可以长达 90 天，这样不仅减轻了您的负担也减少了对动物的伤害。 特点 · 丰富的产品线 大约 600 种 · 可以按客户要求定制您实验需要的药剂 · 丰富的文献引用 · 使长期稳定给药成为可能 · 减少对动物的伤害 产品选择 产品展示如下：您需要选择药物种类・缓释时间、药物剂量、包装等，具体如下 1. 知道一天需要释放的计量就可以选择药物剂量了 平均一天的放出量×缓释时间=产品药物量 2. 药物每天释放量的计算方法计算方法 产品药物剂量 缓释时间 每一天释放剂量 ÷ = 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 使用方法 常用植入方法（所有大小颗粒全部适用） 1. 将动物脖子皮肤轻轻拉起。 2. 在动物脖子处切一个药片大小的口子。 3. 用镊子插入 2 厘米左右。 4. 用镊子将药片植入就可以了。 小颗粒用植入器具（ PRECISION TROCHAR）使用植入方法（颗 粒的直径 3 毫米以下） 1. 先将药片装入小颗粒用植入器。 2. 将动物脖子皮肤轻轻拉起。 3. 用小颗粒用植入器刺穿动物皮肤，将药片植入即可。 *这种方法不需要抗生素和缝合伤口，也没有出血 *本产品使用过程中不能和其他有机溶剂或者其他液体接触和一起 使用。 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 药品种类 大约有 600 中产品可以选择。 A B C D E F G H I K L M N O P Q R S T U V X Y Z 产品编号 释放时间 药品名称 21 天 60 天 90 天 A Acebutolol C-101 SC-101 NC-101 2 -Acetamidofluorene (2-Aaf) A-102 SA-102 NA-102 Acetarsone B-165 SB-165 NB-165 Acetazolamide D-111 SD-111 ND-111 Acetopromazine C-102 SC-102 NC-102 Acetyl-L-Carnitine V-272 SV-272 NV-272 N -Acetyl-L-Cysteine Q-212 SQ-212 NQ-212 N -Acetyl-L-Glutamine Q-272 SQ-272 NQ-272 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 N -Acetylimidazole Q-273 SQ-273 NQ-273 N -Acetylprocainamide C-106 SC-106 NC-106 cis -Aconitic Acid K-111 SK-111 NK-111 trans -Aconitic Acid K-112 SK-112 NK-112 Aconitine K-113 SK-113 NK-113 Actinomycin D (Dactinomycin) Z-110 SZ-110 NZ-110 Adenosine N-111 SN-111 NN-111 Adrenal Cortex Acetone Powder G-116 SG-116 NG-116 Adrenosterone G-117 SG-117 NG-117 Ajmaline C-135 SC-135 NC-135 β-Alanine Q-131 SQ-131 NQ-131 D -Alanine Q-111 SQ-111 NQ-111 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 L -Alanine Q-121 SQ-121 NQ-121 Albendazole B-166 SB-166 NB-166 D -Aldosterone M-151 SM-151 NM-151 Allopurinol I-111 SI-111 NI-111 Alloxan A-103 SA-103 NA-103 Alprenolol C-431 SC-431 NC-431 Althiazide A-104 SA-104 NA-104 Amantadine B-167 SB-167 NB-167 Amcinonide G-118 SG-118 NG-118 Amiloride D-181 SD-181 ND-181 α-Aminoacetophenone A-106 SA-106 NA-106 m -Aminoacetophenone A-107 SA-107 NA-107 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 p -Aminoacetophenone A-108 SA-108 NA-108 Aminoglutethimide G-281 SG-281 NG-281 6 -Aminopenicillanic Acid B-111 SB-111 NB-111 Aminophylline C-125 SC-125 NC-125 Aminopyrine A-109 SA-109 NA-109 Amiodarone A-112 SA-112 NA-112 Amitriptyline C-451 SC-451 NC-451 Amoxicillin B-112 SB-112 NB-112 Amphotericin B B-113 SB-113 NB-113 Ampicillin B-114 SB-114 NB-114 Amrinone C-107 SC-107 NC-107 Androstenediol※ A-131 SA-131 NA-131 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Androstenedione A-121 SA-121 NA-121 5α-Androsterone A-141 SA-141 NA-141 5β-Androsterone A-101 SA-101 NA-101 Anisodamine K-114 SK-114 NK-114 Anisodine K-115 SK-115 NK-115 Antazoline C-461 SC-461 NC-461 Arachidic Acid F-111 SF-111 NF-111 Arachidonic Acid F-161 SF-161 NF-161 Arecoline K-116 SK-116 NK-116 D -Arginine Q-141 SQ-141 NQ-141 L -Arginine Q-151 SQ-151 NQ-151 Asparaginase Z-120 SZ-120 NZ-120 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 D -Asparagine Q-161 SQ-161 NQ-161 L -Asparagine Q-171 SQ-171 NQ-171 D -Aspartic Acid Q-181 SQ-181 NQ-181 L -Aspartic Acid Q-191 SQ-191 NQ-191 Aspirin X-121 SX-121 NX-121 Atenolol C-221 SC-221 NC-221 Atropine K-117 SK-117 NK-117 Atropine Methyl Bromide K-118 SK-118 NK-118 8 -Azaadenine N-121 SN-121 NN-121 5 -Azacytidine N-131 SN-131 NN-131 5 -Azacytosine N-141 SN-141 NN-141 8 -Azaguanine N-151 SN-151 NN-151 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 8 -Azahypoxanthine N-161 SN-161 NN-161 7 -Azaindole N-171 SN-171 NN-171 6 -Azathymine N-181 SN-181 NN-181 5 -Azauracil N-191 SN-191 NN-191 6 -Azauracil N-201 SN-201 NN-201 6 -Azauridine N-211 SN-211 NN-211 B 产品编号 释放时间 药品名称 21 天 21 天 B Bacitracin B-115 SB-115 NB-115 Baclofen B-110 SB-110 NB-110 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Beclomethasone B-116 SB-116 NB-116 Benzylpenicillinic Acid B-117 SB-117 NB-117 Berberine K-119 SK-119 NK-119 Betamethasone G-191 SG-191 NG-191 Boldine K-120 SK-120 NK-120 5 -Bromo-2'-Deoxyuridine (Brdu) N-231 SN-231 NN-231 8 -Bromoadenosine 3':5'-Cyclic N-221 SN-221 NN-221 Monophosphate Bromocriptine Mesylate C-231 SC-231 NC-231 Brucine K-122 SK-122 NK-122 Busulfan (Myleran) Z-130 SZ-130 NZ-130 产品编号 药品名称 释放时间 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 21 天 21 天 C Caffeine C-191 SC-191 NC-191 Calycanthine K-123 SK-123 NK-123 Camptothecin C-116 SC-116 NC-116 Captopril C-117 SC-117 NC-117 Carbamazepine C-113 SC-113 NC-113 Carbinoxamine C-471 SC-471 NC-471 DL -Carnitine V-271 SV-271 NV-271 β-Carotene V-215 SV-215 NV-215 Cefadroxil B-170 SB-170 NB-170 Cefamandole B-171 SB-171 NB-171 Cefazolin B-172 SB-172 NB-172 Cefmetazole B-173 SB-173 NB-173 Cefoperazone B-174 SB-174 NB-174 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Cefotaxime B-175 SB-175 NB-175 Cefoxitin B-176 SB-176 NB-176 Cefsulodin B-177 SB-177 NB-177 Ceftriaxone B-178 SB-178 NB-178 Centrophenoxine (Meclofenoxate) C-115 SC-115 NC-115 Cephalexin B-118 SB-118 NB-118 Cephaloglycin B-119 SB-119 NB-119 Cephalothin B-120 SB-120 NB-120 Cephapirin B-121 SB-121 NB-121 Chlorambucil Z-140 SZ-140 NZ-140 Chloramphenicol X-131 SX-131 NX-131 Chloramphenicol Base B-123 SB-123 NB-123 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Chlorcyclizine C-145 SC-145 NC-145 Chlormadinone Acetate P-221 SP-221 NP-221 Chloroquine I-112 SI-112 NI-112 Chlorothiazide C-155 SC-155 NC-155 Chlorotrianisene E-201 SE-201 NE-201 Chlorpheniramine B-124 SB-124 NB-124 Chlorpromazine C-241 SC-241 NC-241 Chlorthalidone C-175 SC-175 NC-175 Chlorzoxazone C-185 SC-185 NC-185 Cimetidine C-372 SC-372 NC-372 Cinchonidine B-154 SB-154 NB-154 Cinnarizine B-125 SB-125 NB-125 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Clemastine C-120 SC-120 NC-120 Clemizole C-119 SC-119 NC-119 Clenbuterol C-118 SC-118 NC-118 Clofoctol C-104 SC-104 NC-104 Clomiphene Citrate P-211 SP-211 NP-211 Clomipramine C-103 SC-103 NC-103 Clonidine C-251 SC-251 NC-251 Clopamide C-105 SC-105 NC-105 Clotrimazole B-126 SB-126 NB-126 Cloxacillin B-127 SB-127 NB-127 Colchicine B-155 SB-155 NB-155 Cortexolone G-301 SG-301 SG-301 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Cortexolone Acetate G-311 SG-311 NG-311 Corticosterone G-111 SG-111 NG-111 Corticosterone 21 -Acetate G-171 SG-171 NG-171 Cortisone G-121 SG-121 NG-121 Cortisone Acetate G-181 SG-181 NG-181 (-)Cotinine K-124 SK-124 NK-124 Coumarin (1, 2 -Benzopyrone) C-112 SC-112 NC-112 Cromolyn C-195 SC-195 NC-195 Crotaline K-125 SK-125 NK-125 Cyclizine C-108 SC-108 NC-108 Cyclophosphamide (Cytoxan) Z-150 SZ-150 NZ-150 D -Cycloserine B-128 SB-128 NB-128 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Cymarin C-382 SC-382 NC-382 Cyproheptadine C-481 SC-481 NC-481 Cyproterone Acetate C-114 SC-114 NC-114 D -Cysteine Q-201 SQ-201 NQ-201 L -Cysteine Q-211 SQ-211 NQ-211 D -Cystine Q-221 SQ-221 NQ-221 L -Cystine Q-231 SQ-231 NQ-231 Cytarabine (Cytosine Arabinoside) Z-160 SZ-160 NZ-160 Cytisine K-126 SK-126 NK-126 Cytosine N-241 SN-241 NN-241 产品编号 释放时间 药品名称 21 天 60 天 90 天 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 D Danazol P-251 SP-251 NP-251 Daunorubucin Z-170 SZ-170 NZ-170 3 -Deazauracil N-251 SN-251 NN-251 3 -Deazauridine N-261 SN-261 NN-261 Decamethonium Bromide D-112 SD-112 ND-112 Defroxamine Mesylate D-113 SD-113 ND-113 7 -Dehydrocholesterol V-281 SV-281 NV-281 Dehydrocholic Acid D-114 SD-114 ND-114 Dehydroepiandrosterone A-111 SA-111 NA-111 Dehydroepiandrosterone Acetate D-115 SD-115 ND-115 Dehydroepiandrosterone Sulfate D-116 SD-116 ND-116 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 16 -Dehydropregnenolone P-271 SP-271 NP-271 16 -Dehydropregnenolone Acetate P-281 SP-281 NP-281 16 -Dehydroprogesterone P-261 SP-261 NP-261 Demeclocycline D-121 SD-121 ND-121 Deoxycholic Acid D-110 SD-110 ND-110 Deoxycorticosterone (Doc) M-111 SM-111 NM-111 Deoxycorticosterone Acetate (Doca) M-121 SM-121 NM-121 Desipramine C-491 SC-491 NC-491 Desoximetasone D-107 SD-107 ND-107 Dexamethasone G-131 SG-131 NG-131 Dexamethasone 21-Acetate G-201 SG-201 NG-201 Dexamethasone 21-Phosphate D-108 SD-108 ND-108 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 Diaveridine B-129 SB-129 NB-129 N 6 -0 2 N-271 SN-271 NN-271 -Dibutyryladenosine-3':5'-cyclic Monophosphate Diclofenac X-135 SX-135 NX-135 Dicloxacillin B-156 SB-156 NB-156 Dienestrol E-181 SE-181 NE-181 Dienestrol Diacetate E-191 SE-191 NE-191 Diethylstilbestrol (Des) E-151 SE-151 NE-151 Digitoxin C-196 SC-196 NC-196 Digoxin C-271 SC-271 NC-271 Dihydroergotamine K-127 SK-127 NK-127 5β-Dihydrotestosterone D-106 SD-106 ND-106 电话：4006551678 email:[email protected] QQ: 4006551678 中国总代：上海起福生物科技有限公司 产品编号 释放时间 药品名称 21 天 60 天 90 天 5α-Dihydrotestosterone (Controlled A-161 SA-161 NA-161 Substance)※ 3,5 -Diiodo-DL-thyronine T-231 ST-231 NT-231 3,5 -Diiodo-L-thyronine T-241 ST-241 NT-241 Dimenhydrinate
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Labeling and Synthesis of Estrogens and Their Metabolites
    Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2.
    [Show full text]
  • Effects of Chronic Treatment with Testosterone Propionate on Aggression and Hormonal Levels in Intact Male Mice
    Psychoneuroendocrinology, Vol. 23, No. 3, pp. 275–293, 1998 © 1998 Elsevier Science Ltd. All rights reserved Printed in Great Britain 0306-4530/98 $19.00+.00 PII: S0306-4530(97)00005-5 EFFECTS OF CHRONIC TREATMENT WITH TESTOSTERONE PROPIONATE ON AGGRESSION AND HORMONAL LEVELS IN INTACT MALE MICE S. Martı´nez-Sanchis, A. Salvador, L. Moya-Albiol, E. Gonza´lez-Bono and V. M. Simo´n Area de Psicobiologı´a, Facultad de Psicologı´a, Universitat de Vale`ncia, Avenida Blasco Iban˜ez n° 21, Apartado 22109, 46071 Valencia, Spain (Recei6ed 31 January 1997; in final form 22 No6ember 1997) SUMMARY Effects of testosterone propionate, an anabolic-androgenic steroid (AAS), on aggression in gonadally intact male mice were examined. Animals were given weekly injections of 3.75, 7.5, 15, and 30 mg/kg of drug or sesame oil for 10 weeks. During the last 3 weeks, behavioral tests were conducted and at the end of the experiment, body, liver and testes weight and hormonal data were collected. The treatment had minimal behavioral and endocrine effects. It resulted in shorter latencies of ‘threat’ only in the last agonistic encounter, increases in testosterone levels and decreases in testes weight in a non-linear dose-dependant way. The action of the treatment was different on threat and attack, the latter being unaffected. The behavioral effects in the total sample were only found in aggressive animals selected on the basis of their latency of attack in the first encounter. © 1998 Elsevier Science Ltd. All rights reserved. Keywords—AAS; Testosterone; Corticosterone; Aggression; Intact male mice; Individual differences.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Directory of Suppliers
    Directory of Suppliers The directory lists the major suppliers of instruments and acces­ sories. A more complete list can be found in J. Gas Chromatog., June 1965. Suppliers are generally listed under one heading only although many of the large instrument manufacturers supply most of the listed accessories and supplies. INSTRUMENTS AMERICAN INSTRUMENT CO., INC. MICRO-TEK INSTRUMENTS, INC. 8030 Georgia Avenue P. O. Box 15409 Silver Spring, Maryland 20910 Baton Rouge. Louisiana BARBER-COLMAN COMPANY NESTER/FAUST Rockford. Illinois 2401 Ogletown Road Newark, Delaware BECKMAN INSTRUMENTS. INC. 2500 Harbor Boulevard PACKARD INSTRUMENT CO .. INC. Fullerton. California 92634 2200 Warrenville Road Downers Grove, Illinois 60515 BURRELL CORPORATION 2223 Fifth Avenue THE PERKIN-ELMER CORP. Pittsburgh 19, Pennsylvania 870 Main Avenue Norwalk, Connecticut CARY INSTRUMENTS Applied Physics Corporation 2724 South Peck Road WARNER-CHILCOTT LABORATORIES Monrovia, California Instrument Division 200 South Garrard Boulevard F & M SCIENTIFIC CORP. Richmond, California Route 41 and Starr Road Avondale, Pennsyl vania WILKENS INSTRUMENT & RESEARCH INC. 2700 Mitchell Drive, Box 313 GLOWALL CORPORATION Walnut Creek. California 2530 Wyandotte Road Willow Grove, Pennsylvania BECKER-DELFT (Julian H. Becker N.V.) JARRELL-ASH COMPANY Vulcanusweg 113, P. O. Box 219 590 Lincoln Street Delft, Holland Waltham, Massachusetts 02154 BODENSEEWERK PERKIN ELMER & CO. LOENCO, INC. GmbH 2092 North Lincoln Avenue 777 Uberlingen/Bodensee Altadena, California 91002 West Germany 267 268 Directory of Suppliers CARLO ERBA S.p.A. JOHNS-MANVILLE PRODUCTS CORP. Via Carlo Imbonati, 24 Celite Division Milano, Italy 22 East 40th Street New York, New York GAS CHROMATOGRAPHY LIMITED Boyn Valley Road, Maidenhead MAY & BAKER LIMITED Berkshire, England Dagenham Essex, England W.
    [Show full text]
  • Relationship Between Prenatal Characteristics and Body Condition and Endocrine Profile in Rabbits
    animals Article Relationship between Prenatal Characteristics and Body Condition and Endocrine Profile in Rabbits María-Luz García 1,* , Raquel Muelas 1, María-José Argente 1 and Rosa Peiró 2 1 Departamento de Tecnología Agroalimentaria, Universidad Miguel Hernández de Elche, Ctra de Beniel km 3.2, 03312 Orihuela, Spain; [email protected] (R.M.); [email protected] (M.-J.A.) 2 Instituto de Conservación y Mejora de la Agrodiversidad Valenciana, Universitat Politècnica de València, P.O. Box 22012, 46071 Valencia, Spain; [email protected] * Correspondence: [email protected] Simple Summary: Litter size is an essential trait in rabbit production, and it depends on ovulation rate and embryonic and foetal survival. The period between 8 and 18 d of gestation is critical for foetal survival, as the placenta controls foetal nutrition during this period. Ovulation rate and foetal survival at 12 d of gestation are affected by body condition and metabolic and hormonal profile. Higher foetal survival is related to a higher number of vessels arriving at the implantation site, and may be due to higher available space for the foetus. Abstract: This study evaluated the relationship between prenatal characteristics and body condition and endocrine profile. A total of 25 non-lactating multiparous females were used. Body condition, measured as body weight and perirenal fat thickness, non-esterified fatty acids (NEFA), leptin, progesterone and 17β-estradiol were recorded at mating and 12 d of gestation. Ovulation rate, number of foetuses, ovary and foetal weight, length and weight of uterine horn, available space per foetus and maternal and foetal placental morphometry were recorded at 12 d of gestation.
    [Show full text]
  • Expression of Progesterone Receptor Related to the Polymorphism in the PGR Gene in the Rabbit Reproductive Tract1
    Expression of progesterone receptor related to the polymorphism in the PGR gene in the rabbit reproductive tract1 R. Peiró,*2 A. Herrler,† M. A. Santacreu,* M. Merchán,‡ M. J. Argente,§ M. L. García,§ J. M. Folch,‡ and A. Blasco* *Instituto de Ciencia y Tecnología Animal, Universidad Politécnica de Valencia, PO Box 22012, 46071 Valencia, Spain; †Department of Anatomy and Reproductive Biology, Medical School, RWTH University of Aachen, Wendlingweg 2, 52057 Aachen, Germany; ‡Departament de Ciència Animal i dels Aliments, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; and §Departamento de Tecnología Agroalimentaria, Universidad Miguel Hernández de Elche, 03312 Orihuela, Spain ABSTRACT: The association of the 2464G > A SNP AA genotype in the oviduct (GG/AAPR-B = 0.81 and found in the promoter region of the rabbit progester- GG/AAPR-A = 0.73) and uterus (around 0.70 in both one receptor gene with progesterone receptor (PR) ex- isoforms). The GA genotype showed similar PR-A ex- pression was evaluated by Western blot analysis. This pression in both tissues and also similar PR-B expres- SNP was associated with 2 lines divergently selected sion in the oviduct to the GG genotype. Conversely, for uterine capacity, the high line selected to increase the GG genotype showed less PR-B expression than uterine capacity and the low line selected to decrease the GA genotype in the uterus (GG/GAPR-B = 0.79). uterine capacity. Two progesterone isoforms were ob- Similar expression of both PR isoforms was found in tained using a commercial monoclonal antibody: the the uterus at d 2 and 3 of gestation; meanwhile, an PR-B isoform described previously in rabbits, and the increase of both isoforms was observed in the oviduct.
    [Show full text]
  • Synthetic Modifications of Estrogens and Androgens
    Synthetic Modifications of Estrogens and Androgens Somdatta Deb University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Scienec of the University of Helsinki for public criticism in Auditorium A110, Department of Chemistry on June 23rd, 2011, at 12 o’clock. Helsinki 2011 Supervisor Professor Kristiina Wähälä Laboratory of Organic Chemistry Department of Chemistry University of Helsinki Finland Reviewers Professor Erkki Kolehmainen Department of Chemistry University of Jyväskyla Finland Docent Salme Koskimies Adjunct. Professor University of Helsinki Opponent Professor Maria Christina das Neves Oliveira Unidade de Ciências Químicas e Radiofarmacêuticas Portugal ISBN 978-952-92-9174-8 (paperback) ISBN 978-952-10-7051-8 (PDF) Helsinki 2011 Unigrafia Acknowledgements This thesis work was carried out at the Laboratory of Organic Chemistry, Department of Chemistry, University of Helsinki. I would like to express my deep gratitude to my supervisor Prof. Kristiina Wähälä for introducing me to the fascinating field of steroid chemistry and for providing the facilities to do this work. I warmly thank emeritus professor Tapio Hase for his helpful, invaluable scientific advice during my work. Prof. Matti J. Tikkananen and his group are gratefully acknowledged for pleasant collaboration. My warmest thanks are due to all personnel in the Laboratory of Organic Chemistry, specially the members (former and present) of Phyto-Syn group for their support. They have been always there when needed. In particular I would like to thank Gudrun Silvennoinen for technical assistance and friendship. I am thankful to Dr. Ullastiina Hakala for introducing me to the field of ionic liquid.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,068,830 Diamandis Et Al
    US00606883OA United States Patent (19) 11 Patent Number: 6,068,830 Diamandis et al. (45) Date of Patent: May 30, 2000 54) LOCALIZATION AND THERAPY OF FOREIGN PATENT DOCUMENTS NON-PROSTATIC ENDOCRINE CANCER 0217577 4/1987 European Pat. Off.. WITH AGENTS DIRECTED AGAINST 0453082 10/1991 European Pat. Off.. PROSTATE SPECIFIC ANTIGEN WO 92/O1936 2/1992 European Pat. Off.. WO 93/O1831 2/1993 European Pat. Off.. 75 Inventors: Eleftherios P. Diamandis, Toronto; Russell Redshaw, Nepean, both of OTHER PUBLICATIONS Canada Clinical BioChemistry vol. 27, No. 2, (Yu, He et al), pp. 73 Assignee: Nordion International Inc., Canada 75-79, dated Apr. 27, 1994. Database Biosis BioSciences Information Service, AN 21 Appl. No.: 08/569,206 94:393008 & Journal of Clinical Laboratory Analysis, vol. 8, No. 4, (Yu, He et al), pp. 251-253, dated 1994. 22 PCT Filed: Jul. 14, 1994 Bas. Appl. Histochem, Vol. 33, No. 1, (Papotti, M. et al), 86 PCT No.: PCT/CA94/00392 Pavia pp. 25–29 dated 1989. S371 Date: Apr. 11, 1996 Primary Examiner Yvonne Eyler S 102(e) Date: Apr. 11, 1996 Attorney, Agent, or Firm-Banner & Witcoff, Ltd. 87 PCT Pub. No.: WO95/02424 57 ABSTRACT It was discovered that prostate-specific antigen is produced PCT Pub. Date:Jan. 26, 1995 by non-proStatic endocrine cancers. It was further discov 30 Foreign Application Priority Data ered that non-prostatic endocrine cancers with Steroid recep tors can be stimulated with Steroids to cause them to produce Jul. 14, 1993 GB United Kingdom ................... 93.14623 PSA either initially or at increased levels.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Wo 2009/132050 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132050 A2 (51) International Patent Classification: 61/101,1 12 29 September 2008 (29.09.2008) US A61K 39/395 (2006.01) A61K 47/34 (2006.01) 61/140,033 22 December 2008 (22. 12.2008) US A61P 27/16 (2006.01) A61K 9/06 (2006.01) 61/160,233 13 March 2009 (13.03.2009) US (21) International Application Number: (71) Applicants (for all designated States except US): OTON- PCT/US2009/041320 OMY, INC. [US/US]; 5626 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). THE REGENTS OF THE (22) International Filing Date: UNIVERSITY OF CALIFORNIA [US/US]; 1111 2 1 April 2009 (21 .04.2009) Franklin Street, 12th Floor, Oakland, CA 94607 (US). (25) Filing Language: English (72) Inventors; and (26) Publication Language: English (75) Inventors/Applicants (for US only): LICHTER, Jay [US/US]; P.O. Box 676244, Rancho Santa Fe, CA 92067 (30) Priority Data: (US). VOLLRATH, Benedikt [DE/US]; 4704 Niagara 61/046,543 2 1 April 2008 (21 .04.2008) US Avenue, San Diego, CA 92107 (US). TRAMMEL, An¬ 61/048,878 29 April 2008 (29.04.2008) US drew, M. [US/US]; 12485 South Alden Circle, Olathe, 61/127,7 13 14 May 2008 (14.05.2008) us KS 66062 (US). DURON, Sergio, G. [US/US]; 1605 61/055,625 23 May 2008 (23.05.2008) us Neale Street, San Diego, CA 92103 (US).
    [Show full text]
  • Développement De Modèles Prédictifs De La Toxicocinétique De Substances Organiques
    Université de Montréal Développement de modèles prédictifs de la toxicocinétique de substances organiques par Thomas Peyret Département de santé environnementale et santé au travail Faculté de Médecine Thèse présentée à la Faculté de Médecine en vue de l’obtention du grade de Ph.D. en Santé Publique option Toxicologie et analyse du risque Février, 2013 © Peyret, 2013 Université de Montréal Faculté des études supérieures et postdoctorales Cette thèse intitulée : Développement de modèles prédictifs de la toxicocinétique de substances organiques Présentée par : Thomas Peyret a été évaluée par un jury composé des personnes suivantes : Marc Baril, président-rapporteur Kannan Krishnan, directeur de recherche Ginette Truchon, membre du jury Yumei Cecilia Tan, examinateur externe Patrick du Souich, représentant du doyen de la FESP Résumé Les modèles pharmacocinétiques à base physiologique (PBPK) permettent de simuler la dose interne de substances chimiques sur la base de paramètres spécifiques à l’espèce et à la substance. Les modèles de relation quantitative structure-propriété (QSPR) existants permettent d’estimer les paramètres spécifiques au produit (coefficients de partage (PC) et constantes de métabolisme) mais leur domaine d’application est limité par leur manque de considération de la variabilité de leurs paramètres d’entrée ainsi que par leur domaine d’application restreint (c. à d., substances contenant CH3, CH2, CH, C, C=C, H, Cl, F, Br, cycle benzénique et H sur le cycle benzénique). L’objectif de cette étude est de développer de nouvelles connaissances et des outils afin d’élargir le domaine d’application des modèles QSPR-PBPK pour prédire la toxicocinétique de substances organiques inhalées chez l’humain.
    [Show full text]